Biomed

Biomed Technology Holdings Limited operates as a biomedical technology firm focused on microbiome-based health solutions, positioning itself at the intersection of biotechnology and personalized medicine. Incorporated in Hong Kong on September 10, 2018, the company was co-founded by CEO Vincent Tsang, Professor Stephen Tsui, and Dr. Steven Loo, leveraging their collective expertise in business, biomedical sciences, and clinical dermatology. Mr. Tsang brings a strong background in technology and business, having previously founded a company that was listed on the Hong Kong GEM. Professor Tsui serves as the R&D Principal Consultant, and Dr. Loo as the Medical Director.

The company's core business revolves around a three-pronged approach to gut health: microbiome DNA testing, personalized dietary recommendations, and the provision of tailor-made probiotic, prebiotic, and postbiotic supplements under its PGut brand. It serves both individual consumers (B2C) and other healthcare service providers (B2B). On the B2C front, its PGut products are available in over 300 retail outlets, including major chains like Mannings. For its B2B operations, Biomed has partnered with over 200 healthcare providers to deliver its testing services. The business generates revenue through the sale of its testing kits and proprietary supplement products, as well as through collaborations with healthcare centers.

The primary service is a gut microbiome DNA test, which analyzes fecal samples using 16S rRNA sequencing and qPCR technology to assess the health of an individual's gut flora. Based on the test results, which are validated by registered medical laboratory technologists, the company provides personalized health management plans. This includes recommendations for its line of PGut probiotic formulas, which are formulated with specific strains and combined with prebiotics and postbiotics to address issues uncovered in the analysis, such as allergies, skin conditions, and metabolic syndromes. A key asset is its microbiome database, which contains over 10,000 profiles, primarily from Hong Kong, enabling data-driven solutions tailored to the local population. The firm is also expanding its research into oral and skin microbiomes and has entered the pet healthcare market, developing microbiome tests for cats and dogs.

Nurtured by the Hong Kong Science and Technology Parks Corporation (HKSTP), BioMed has secured significant financial backing. In April 2023, it announced a USD 2 million seed round from investors including Alibaba Hong Kong Entrepreneurs Fund (AEF), Gobi Partners GBA, and The International Medical Co. Ltd. (TIMC). This was followed by strategic investments from Human Health Holdings and CUHK Innovation Limited. These funds are earmarked for further research and development, as well as expansion into mainland China and other parts of Asia.

Keywords: microbiome testing, gut health, probiotics, personalized medicine, DNA testing, biomedical technology, gut flora analysis, dietary supplements, prebiotic, postbiotic, PGut, Hong Kong biotech, skin microbiome, oral microbiome, pet microbiome, allergy solutions, eczema treatment, metabolic syndrome management, scientific wellness, gut-brain axis